Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc T.MBX

Alternate Symbol(s):  MBXBF

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.


TSX:MBX - Post by User

Post by Mbxwatcheron Mar 31, 2021 12:11pm
226 Views
Post# 32914472

Toronto Vaccine plant?

Toronto Vaccine plant?

TORONTO -- The governments of Canada and Ontario are investing in a new influenza vaccine manufacturing facility in Toronto, sources tell The Canadian Press.

Sources say the federal government will invest $415 million in the partnership with Sanofi Pasteur Ltd.

Ontario's government will contribute $55 million to the project, according to the sources.

Sanofi will invest more than $455 million as well as create and maintain 1,225 highly skilled jobs in Canada.

The company will also invest at least $79 million a year to fund Canadian research and development.

 

This new facility will ensure drug product formulation, fill-and-finish and inspection of flu vaccines.

Is it just me or should this be a big deal for MBX?  I know we don't make vaccines, but depending on the formulation could we be a significant supplier to such a company?   Legitimately asking brighter minds than my own.

<< Previous
Bullboard Posts
Next >>